Back to search
FDAFDA · Food and drugs·Recall number D-0048-2024

Doxil (doxorubicin hydrochloride liposome injection) 50 mg in 25 mL (2 mg/mL), Single-Dose Vial, Rx only, Manufactured for: Baxter Healthcare Corporation, Deerfield, IL 60015. NDC 0338-0067-01

Published October 25, 2023 · Recall initiated: August 24, 2023

Summary

FDA records drug Class II recall D-0048-2024, published October 25, 2023 and initiated August 24, 2023. Recalling firm: Baxter Healthcare Corporation; Status: Terminated; Reported quantity: 472 vials; Lot: Lot# MKZSU02, Exp 6/30/2024. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Product was exposed to temperatures exceeding the labeled storage conditions during transportation were released by mistake.

What to do

Voluntary: Firm initiated · Letter

Get an email if DOXIL has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
DOXIL
Manufacturer
Baxter Healthcare Corporation
Distributor
Nationwide in the USA
Lot
Lot# MKZSU02, Exp 6/30/2024
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Doxil (doxorubicin hydrochloride liposome injection) 50 mg in 25 mL (2 mg/mL), Single-Dose Vial, Rx only, Manufactured for: Baxter Healthcare Corporation, Deerfield, IL 60015. NDC 0338-0067-01 recalled?

Yes. FDA published recall D-0048-2024 on October 25, 2023. Reported hazard: CGMP Deviations: Product was exposed to temperatures exceeding the labeled storage conditions during transportation were released by mistake.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: DOXIL.